BlockBeats News, January 14th, more and more options traders are excluding the expectation of a Fed rate cut in 2026 and are instead betting on it maintaining the interest rate unchanged throughout the year. This trend can be traced back to at least last Friday when U.S. employment data showed an unexpected drop in the unemployment rate. According to market pricing, this has almost eliminated the possibility of a Fed rate cut this month, prompting more and more traders to postpone their expectations for a rate cut in the coming months. TJM Institutional Services interest rate strategist David Robin pointed out: "From a data perspective, the probability that the Fed will keep rates unchanged at least until March has increased, and as each meeting passes, the likelihood of rate stability increases." The options flow closely linked to the Fed's short-term benchmark rate has recently conveyed a more hawkish signal.
New option positions are mainly concentrated in March and June contracts to hedge against a scenario where the Fed's next rate cut action is continuously delayed. Positions targeting longer-dated contracts are expected to benefit from the Fed's stance of keeping rates unchanged throughout the year. Robin stated that the cost of these trades is low regardless of whether the market believes the Fed will stand pat. As a prudent risk manager, you would want to hold such positions. (FX678)
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.









Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.